Stock Analysis

Edan Instruments, Inc.'s (SZSE:300206) 26% Price Boost Is Out Of Tune With Earnings

Edan Instruments, Inc. (SZSE:300206) shares have had a really impressive month, gaining 26% after a shaky period beforehand. The last 30 days bring the annual gain to a very sharp 38%.

Since its price has surged higher, Edan Instruments' price-to-earnings (or "P/E") ratio of 47.8x might make it look like a sell right now compared to the market in China, where around half of the companies have P/E ratios below 36x and even P/E's below 20x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.

As an illustration, earnings have deteriorated at Edan Instruments over the last year, which is not ideal at all. It might be that many expect the company to still outplay most other companies over the coming period, which has kept the P/E from collapsing. If not, then existing shareholders may be quite nervous about the viability of the share price.

Check out our latest analysis for Edan Instruments

pe-multiple-vs-industry
SZSE:300206 Price to Earnings Ratio vs Industry February 10th 2025
We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Edan Instruments' earnings, revenue and cash flow.

What Are Growth Metrics Telling Us About The High P/E?

The only time you'd be truly comfortable seeing a P/E as high as Edan Instruments' is when the company's growth is on track to outshine the market.

Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 44%. This means it has also seen a slide in earnings over the longer-term as EPS is down 42% in total over the last three years. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.

In contrast to the company, the rest of the market is expected to grow by 38% over the next year, which really puts the company's recent medium-term earnings decline into perspective.

In light of this, it's alarming that Edan Instruments' P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as a continuation of recent earnings trends is likely to weigh heavily on the share price eventually.

The Key Takeaway

The large bounce in Edan Instruments' shares has lifted the company's P/E to a fairly high level. While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

We've established that Edan Instruments currently trades on a much higher than expected P/E since its recent earnings have been in decline over the medium-term. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.

And what about other risks? Every company has them, and we've spotted 4 warning signs for Edan Instruments (of which 1 shouldn't be ignored!) you should know about.

If these risks are making you reconsider your opinion on Edan Instruments, explore our interactive list of high quality stocks to get an idea of what else is out there.

The New Payments ETF Is Live on NASDAQ:

Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.

Explore how this launch could reshape portfolios

Sponsored Content

Valuation is complex, but we're here to simplify it.

Discover if Edan Instruments might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SZSE:300206

Edan Instruments

Engages in the research, development, manufacture, and service of medical electronic equipment and in vitro diagnostic products in China and internationally.

Flawless balance sheet with proven track record and pays a dividend.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
22 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
3 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KI
RKLB logo
KiwiInvest on Rocket Lab ·

Rocket Lab USA Will Ignite a 30% Revenue Growth Journey

Fair Value:US$97.8335.1% undervalued
137 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative
BA
Bauyrzhan
DG logo
Bauyrzhan on Dollar General ·

Dollar general to grow

Fair Value:US$158.916.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative